8c393f1d2548fc6f4d2553fd4ed7c7cfd463a8af7f039dad5c1945a0df739f46
Licensed Research: Diabetes Mechanism Analysis
Publicly online since 2010 · U.S. patent applications since 2012 · inventions offered since 2014. The work of Christopher Gabriel Brown, independently documented.
This item is delivered by Christopher Gabriel Brown by email within 24 hours of your order. You'll receive the deliverable at the email on your order. USA delivery only. Founder Access Pass credit (code FAP99CREDIT) applies at checkout automatically.
Research: Diabetes Mechanism Analysis
Computational elemental-overlap research from the Alchemy Data V2 system — 14 compound candidates spanning beta cell regeneration, insulin regeneration, glucose metabolism, cell regeneration, and growth factors
This product is research, not medicine. The Alchemy Data V2 system is a computational database that finds elemental compositions whose constituents overlap with mechanisms documented in the published diabetes literature — beta cell regeneration, insulin regeneration, glucose metabolism restoration, cell regeneration, growth factors. It surfaces overlap; it does not prove cure.
The findings have been filed at the USPTO as a patent application (application number assignment pending). The product packages the findings, the methodology, the patent application text, and the open-research license terms together as one acquisition.
SAFETY_DISCLAIMER.md for full warnings.14 candidate compounds. 5 mechanism categories — all matched. Computational elemental-overlap on the published zinc-amino-acid diabetes literature.
Research: Diabetes Mechanism Analysis is the productised acquisition of Project 10 — a computational research package built on the Alchemy Data V2 elemental-analysis system. It identifies elemental compositions whose constituents overlap with documented diabetes mechanisms. The top finding is the C-H-O-N-Zn (Carbon-Hydrogen-Oxygen-Nitrogen-Zinc) complex with an Alchemy Score of 50.0/100, 23 synthesis methods available, 99% database match rate, and overlap across all 5 mechanism categories. The finding aligns with active published research on zinc-amino-acid complexes for diabetes treatment.
Findings — what's in the package
- 14 compound candidates identified and analyzed through Alchemy Data V2.
- Top finding: C-H-O-N-Zn — Alchemy Score 50.0/100, 23 synthesis methods, 99% database match rate, mechanism overlap across all 5 categories.
- Top 5 candidates: C-H-O-N-Zn (23 processes, all mechanisms), C-H-O-N-Zn-Mg (23 processes, complete package), C-H-O-N-Ca-Zn (27 processes, most processes), C-H-O-N-S-Zn (25 processes, sulfur bridges), C-H-O-N-P-Zn (23 processes, phosphorylation).
- Statistics: top score 50.0/100, average 22 processes per compound, 99% database match rates across all candidates.
Mechanism categories identified
- Beta cell regeneration — 5 compounds.
- Insulin regeneration — 7 compounds.
- Glucose metabolism restoration — 8 compounds.
- Cell regeneration — 4 compounds.
- Growth factors — 7 compounds.
Scientific context (from the published literature)
The C-H-O-N-Zn finding overlaps with active published research on zinc-amino-acid complexes for diabetes treatment. Documented properties from the literature include:
- Insulin-mimetic effects in animal models: lowers blood glucose in type 2 diabetic mice, improves glucose tolerance, normalizes hyperglycemia, reduces HbA1c, outperforms zinc sulfate.
- Mechanisms in the literature: inhibits free fatty acid release, enhances glucose uptake in adipocytes, activates the insulin signaling pathway, phosphorylates insulin receptor beta-subunit, activates Akt protein, enhances glycogen synthesis.
- Specific complexes studied: Zinc-L-Threonine Complex; Zinc(II)/Poly(gamma-glutamic acid) Complex (21-day oral administration studies); multiple other zinc-amino-acid complexes under investigation.
The literature establishes that zinc-amino-acid complexes are an active diabetes-research area. The Alchemy Data V2 finding does not duplicate any specific published compound — it identifies the elemental composition family that those published compounds belong to, and surfaces additional candidate compositions in the same family.
Methodology — what this is and isn't
The Alchemy Data V2 system is a correlation-finding tool. It searches elemental compositions and ranks them by overlap with mechanism categories documented in the published literature. It is not a clinical drug discovery pipeline. Discovery scores reflect database coverage and elemental match, not therapeutic probability. The bundled METHODOLOGY.md spells out exactly what the system does and does not establish.
The candidate compounds have not been synthesized for this project, have not been tested in humans, and have not been approved for medical use by any regulator. The package is for computational-research use, IP licensing, and follow-on lab work by qualified investigators.
Patent foundation
| Field | Value |
|---|---|
| USPTO Application | Filed; application number assignment pending. Verify at USPTO Patent Center. |
| Type | Utility (non-provisional) |
| Subject | Diabetes Cure Discovery — 14 compound candidates spanning beta cell regeneration, insulin regeneration, glucose metabolism restoration, cell regeneration, and growth factors |
| Status | Filed, awaiting application number assignment and examination — not yet granted. Verify live at patentcenter.uspto.gov. |
| Inventor | Christopher Gabriel Brown |
What ships in the package
- README.md with the full overview, findings, and statistics.
- DIABETES_CURE_PATENT_APPLICATION.md — the patent application text as filed.
- PATENT_FILING_RECEIPT.md — the USPTO filing receipt record (application number to be assigned).
- findings/ directory — final report, summary, known-properties report (V1 + V2 extended).
- METHODOLOGY.md — the Alchemy Data V2 methodology explanation.
- SAFETY_DISCLAIMER.md — safety warnings and known toxicity considerations.
- Patent drawings (4 SVGs) — chemical structures, synthesis scheme, coordination structures, pharmaceutical formulations.
- Research reference chart (11×17 SVG) and formulation chart (11×17 SVG).
- diabetes121212.html — the USPTO Patent Center submission receipt.
- WEB_DESCRIPTION.html, START_HERE.html, CITATION.cff, LICENSE, IP_NOTICE.md, CHANGELOG.md, MANIFEST.json.
How it's made
The work was conducted by running the Alchemy Data V2 system against the diabetes-mechanism category set: beta cell regeneration, insulin regeneration, glucose metabolism restoration, cell regeneration, growth factors. The system enumerated elemental compositions, scored them by transformation count, synthesis-method count, and database match rate, then cross-referenced the top candidates against the published zinc-amino-acid diabetes literature. C-H-O-N-Zn emerged as the top finding because it overlaps with the elements involved in published zinc-amino-acid complexes that have demonstrated insulin-mimetic effects in animal models. The findings were written up as a patent application and filed.
What it can do
The acquired package delivers the research findings, the patent application text, the supporting filing record, the methodology, the safety disclaimers, and the open-research license. A buyer can use the findings as input to wet-lab investigation, as input to a downstream drug-discovery pipeline, or as a citable patent-application reference. The buyer also acquires the right to make, build, and copy the package contents.
What this acquisition does not deliver: clinical-trial data on the specific candidate compounds (none exists yet), regulatory approval (none granted), synthesised compound samples (none included), or assignment of the underlying patent application. The diabetes patent application remains the inventor's filed application.
License Terms — What's Granted, What Isn't
The acquisition grants the buyer permission to make, build, and copy the deliverable. It does not transfer the underlying intellectual property:
- Granted: permission to use the findings as research input; permission to copy the documentation; permission to build follow-on research and synthesis work against the candidate compositions.
- Not transferred: the underlying USPTO patent application, the Alchemy Data V2 system itself, trademarks, copyrights. IP remains held by Christopher Gabriel Brown.
Buyers seeking IP assignment rather than make/build/copy permission should contact the inventor directly.
Open computational research. 14 candidates. USPTO filed (number pending). Permission to make, build, and copy.
The diabetes mechanism-overlap research package, productised.
One acquisition delivers Project 10 in full: the Alchemy Data V2 findings (14 candidates, 5 mechanism categories all matched, top candidate C-H-O-N-Zn at Alchemy Score 50.0/100 with 99% database match rate), the patent application text, the methodology and safety disclaimers, and the open-research license. The work has been filed at the USPTO; application number assignment is pending.
$10,200,000 — Ten Million Two Hundred Thousand USD
Computational research. Not medical advice. Not a clinically validated treatment. Permission to make, build, and copy. IP retained by Christopher Gabriel Brown. Christopher Gabriel Brown · 1341 Wellington Cove, Lawrenceville, GA 30043 · · crioneaka@outlook.com.
